Tag #Pancreatic Cancer

Showing 1 to 12 of 15 results

news.sky.com

🌐 85% Global Worthiness

Aug 11, 19:19

Pancreatic Cancer Vaccine Shows Promise in Early Trials

A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...

Pancreatic Cancer Vaccine Shows Promise in Early Trials

A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the new pancreatic cancer vaccine's success in early trials?

A new pancreatic cancer vaccine, ELI-002 2P, has shown promise in a phase 1 trial by slowing disease progression and increasing survival rates. In a study of 25 patients (20 with pancreatic cancer, 5 with bowel cancer), 68% developed a strong immune response after 20 months. Pancreatic cancer patients receiving the vaccine survived an average of 2 years and 5 months, significantly longer than the current average of one year.

elpais.com

🌐 85% Global Worthiness

Aug 11, 22:16

Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations

An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.

Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations

An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the promising results from the ELI-002 vaccine trial for pancreatic cancer patients?

In Spain, cancer survival rates have doubled in the last four decades, reaching 55% for men and 62% for women five years post-diagnosis. A new experimental cancer vaccine, ELI-002, shows promising results in a small trial, extending the time before cancer recurrence in patients with pancreatic cancer who had undergone surgery and chemotherapy.

elpais.com

🌐 85% Global Worthiness

Apr 15, 19:17

Intracellular Galectin-1 in Pancreatic Cancer Stroma Drives Aggressiveness

An international study published in PNAS identifies Galectin-1 (Gal1) within the nuclei of pancreatic cancer stroma fibroblasts as a key driver of tumor aggressiveness, opening avenues for new therapeutic strategies targeting this protein's intracellular function to improve treatment response in thi...

Intracellular Galectin-1 in Pancreatic Cancer Stroma Drives Aggressiveness

An international study published in PNAS identifies Galectin-1 (Gal1) within the nuclei of pancreatic cancer stroma fibroblasts as a key driver of tumor aggressiveness, opening avenues for new therapeutic strategies targeting this protein's intracellular function to improve treatment response in thi...

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the newly discovered role of Galectin-1 (Gal1) within pancreatic cancer stroma contribute to the disease's aggressive nature and poor prognosis?

Pancreatic cancer's aggressive nature stems from its surrounding stroma, a dense, protective layer shielding tumor cells from the immune system and drugs. This stroma comprises most of the tumor mass, contributing to the low 5-year survival rate (just over 10%). A new study identifies Galectin-1 (Gal1) as a key player in this aggressive behavior.

foxnews.com

🌐 85% Global Worthiness

Mar 16, 01:10

Stress, Obesity Magnify Pancreatic Cancer Risk in Mice: Study

UCLA research shows that stress and obesity significantly increase pancreatic cancer risk in mice, accelerating precancerous lesion growth, especially in females, by activating CREB, suggesting potential for repurposing beta-blockers for prevention.

Stress, Obesity Magnify Pancreatic Cancer Risk in Mice: Study

UCLA research shows that stress and obesity significantly increase pancreatic cancer risk in mice, accelerating precancerous lesion growth, especially in females, by activating CREB, suggesting potential for repurposing beta-blockers for prevention.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do combined stress and obesity impact pancreatic cancer development, and what are the immediate implications for preventative strategies?

A UCLA study revealed that combined stress and obesity significantly increase pancreatic cancer risk in mice, accelerating precancerous lesion growth, particularly in females. This finding highlights a crucial link between lifestyle factors and aggressive cancer development.

abcnews.go.com

🌐 85% Global Worthiness

Feb 20, 04:09

Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer

A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...

Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer

A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of this preliminary study on pancreatic cancer treatment?

A preliminary study suggests a personalized mRNA vaccine may significantly extend survival rates for pancreatic cancer patients. In a small trial, half of the participants (8 out of 16) mounted a strong immune response, remaining cancer-free for over three years—a period far exceeding typical survival rates. This contrasts sharply with the non-responders.

nbcnews.com

🌐 85% Global Worthiness

Feb 19, 19:15

Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment

A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.

Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment

A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this trial challenge previous assumptions about the suitability of mRNA vaccines for treating pancreatic cancer, and what are the underlying reasons for this success?

This study challenges the assumption that pancreatic cancer's limited mutational targets hinder mRNA vaccine efficacy. The success in generating durable T-cell responses in half of the participants, despite the disease's aggressive spread, suggests a potential new approach to treating this deadly cancer. The vaccine's ability to target unique tumor mutations and the longevity of the T-cell response are key advancements.

tr.euronews.com

🌐 85% Global Worthiness

Aug 11, 22:16

Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients

A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.

Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients

A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this off-the-shelf cancer vaccine approach compare to other experimental cancer vaccines, and what are the broader implications of its mass-producibility?

The study involved 25 patients (20 with pancreatic cancer, 5 with colorectal cancer) who had completed standard treatment but still showed signs of cancer. The off-the-shelf vaccine, unlike many experimental cancer vaccines, is mass-produced, not personalized. Patients with the strongest immune response lived longer and remained cancer-free for longer periods.

bbc.com

🌐 85% Global Worthiness

Jun 2, 04:08

Creon Shortage Cripples UK Cancer Patients

A critical shortage of Creon, a pancreatic enzyme needed by over 61,000 UK patients, is causing severe hardship, forcing patients to ration medication and impacting their treatment. The shortage, lasting over a year, is due to European-wide manufacturing issues despite government interventions.

Creon Shortage Cripples UK Cancer Patients

A critical shortage of Creon, a pancreatic enzyme needed by over 61,000 UK patients, is causing severe hardship, forcing patients to ration medication and impacting their treatment. The shortage, lasting over a year, is due to European-wide manufacturing issues despite government interventions.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of the Creon shortage for pancreatic cancer patients in the UK, and how is the government responding?

A critical shortage of Creon, a pancreatic enzyme vital for over 61,000 UK patients with conditions like pancreatic cancer, is causing severe hardship. Patients are skipping meals to ration their medication, impacting their health and ability to endure cancer treatments like chemotherapy. The shortage, attributed to European-wide manufacturing constraints, has persisted for over a year, despite government intervention and a serious shortage protocol.

welt.de

🌐 85% Global Worthiness

Mar 26, 16:12

New Blood Test Shows Promise for Early Pancreatic Cancer Detection

Researchers in Zurich and Portland have developed a blood test that detects pancreatic cancer in early stages with 73% accuracy, offering hope against this deadly disease with a historically low survival rate due to late diagnosis.

New Blood Test Shows Promise for Early Pancreatic Cancer Detection

Researchers in Zurich and Portland have developed a blood test that detects pancreatic cancer in early stages with 73% accuracy, offering hope against this deadly disease with a historically low survival rate due to late diagnosis.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the new blood test work, and what specific biological markers does it target?

The new blood test targets matrix metalloproteinases (MMPs), enzymes that break down proteins and are highly active in the early stages of pancreatic cancer. These MMPs are found in the extracellular matrix, and the nanosensors detect them, allowing for early diagnosis. The test's high accuracy in identifying healthy individuals (98%) is particularly noteworthy.

news.sky.com

🌐 85% Global Worthiness

Feb 28, 16:10

UK Faces Creon Shortage, Affecting Thousands

A shortage of Creon, a crucial pancreatic enzyme drug, is affecting approximately 61,152 people in the UK due to global supply chain issues, with potential implications for pancreatic cancer treatment and lasting until at least 2026.

UK Faces Creon Shortage, Affecting Thousands

A shortage of Creon, a crucial pancreatic enzyme drug, is affecting approximately 61,152 people in the UK due to global supply chain issues, with potential implications for pancreatic cancer treatment and lasting until at least 2026.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the primary causes of the Creon shortage, and how are alternative PERT medications affected?

Global supply chain problems, including limited raw ingredients and manufacturing capacity constraints, are causing the Creon shortage. Alternative PERT medications, Nutrizym and Pancrex, also face supply issues, exacerbating the crisis. The lack of sufficient Creon forces patients to reduce dosages, change diets, and experience worsening symptoms, impacting their quality of life and access to optimal treatment.

forbes.com

🌐 90% Global Worthiness

Feb 19, 01:08

New Blood Test Improves Pancreatic Cancer Diagnosis and Treatment

A new blood test, PAC-MANN, accurately diagnoses pancreatic cancer 98% of the time by detecting protease enzyme activity, offering earlier detection and improved treatment options; when combined with the CA 19-9 test, accuracy for early detection increases to 85%.

New Blood Test Improves Pancreatic Cancer Diagnosis and Treatment

A new blood test, PAC-MANN, accurately diagnoses pancreatic cancer 98% of the time by detecting protease enzyme activity, offering earlier detection and improved treatment options; when combined with the CA 19-9 test, accuracy for early detection increases to 85%.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the new blood test, PAC-MANN, improve the current poor prognosis of pancreatic cancer, and what is its potential impact on global mortality rates?

A new blood test, PAC-MANN, accurately identifies pancreatic cancer in 98% of cases by detecting protease enzyme activity. This early detection, achieved through a simple blood test, offers more treatment options and improves survival rates, significantly impacting the current dismal prognosis of only 13% five-year survival.

cbsnews.com

🌐 85% Global Worthiness

Feb 19, 19:15

mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer

A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...

mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer

A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the successful mRNA vaccine trial for early-stage pancreatic cancer patients?

A clinical trial at Memorial Sloan Kettering Cancer Center combined surgery, chemotherapy, and a customized mRNA vaccine for early-stage pancreatic cancer. Eight of sixteen patients showed strong immune responses, with only two experiencing cancer recurrence after 3.2 years. This contrasts with the typical recurrence within a year for similar patients treated with standard methods.

Showing 1 to 12 of 15 results